<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        90-15-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BYETTA 5 mcg/ml solution for injection pre-filled pen
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        EXENATIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        µ/ml
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Pre-filled pen
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        165.15
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAXTER PHARMACEUTICAL SOLUTION LLC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAXTER PHARMACEUTICAL SOLUTION LLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            AstraZeneca
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        A10BX04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>BYETTA contains the active substance exenatide and is used to improve blood sugar control in adults<br />with type 2 (non insulin dependent) diabetes mellitus.<br />BYETTA is used with other diabetic medicines called metformin, sulphonylureas, thiazolidinediones<br />and basal or long acting insulins. Your doctor is now prescribing BYETTA as an additional medicine<br />to help control your blood sugar. Continue to follow your food and exercise plan.<br />You have diabetes because your body does not make enough insulin to control the level of sugar in<br />your blood or if your body is not able to use the insulin properly. BYETTA helps your body to<br />increase the production of insulin when your blood sugar is high.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use BYETTA</strong><br />- If you are allergic (hypersensitive) to exenatide or any of the other ingredients of BYETTA,<br />listed at the end of this leaflet.<br /><strong>Take special care with BYETTA</strong><br />- When using it in combination with a sulphonylurea, as low blood sugar (hypoglycaemia) can<br />occur. Ask your doctor or pharmacist if you are not sure if any of your other medicines contain a<br />sulphonylurea.<br />- BYETTA should not be used if you have type 1 diabetes or diabetic ketoacidosis (a dangerous<br />condition that can occur in diabetes).<br />- BYETTA should be injected under the skin and not into a vein or into the muscle.<br />- If you have severe problems with your stomach emptying (including gastroparesis) or food<br />digestion the use of BYETTA is not recommended. BYETTA slows stomach emptying so food<br />passes more slowly through your stomach.<br />- Tell your doctor if you have ever had inflammation of the pancreas (pancreatitis) (see section 4).<br />- There is little experience with BYETTA in patients with a BMI (body mass index) &le;25.<br />- There is little experience with BYETTA in patients with kidney problems. The use of BYETTA<br />is not recommended if you have severe kidney disease or you are on dialysis.</p><p><strong>Children and adolescents</strong><br />There is no experience with BYETTA in children and adolescents less than 18 years and, therefore,<br />use of BYETTA is not recommended in this age group.<br /><strong>Using other medicines</strong><br />Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines (for<br />example warfarin) including medicines obtained without a prescription.<br />Ask your doctor if the time at which you take any tablets should be changed because BYETTA slows<br />stomach emptying and can affect medicines that need to pass through the stomach quickly.</p><p>Stomach resistant tablets or capsules (for example proton pump inhibitors) that should not stay too<br />long in your stomach may need to be taken an hour before, or four hours after BYETTA.<br />Some antibiotics may need to be taken an hour before your BYETTA injection.<br />For tablets that you need to take with food, it may be best if they are taken at a meal at a time when<br />BYETTA is not being administered.<br />The use of BYETTA with other medicines that are used to treat type 2 diabetes that work like<br />BYETTA (for example:liraglutide and BYDUREON [exenatide once weekly]), is not recommended.<br /><strong>Using BYETTA with food and drink</strong><br />Use BYETTA at any time within the 60 minutes (1 hour) before your meal. (See 3 &ldquo;How to use<br />BYETTA&rdquo;). Do not use BYETTA after your meal.<br /><strong>Pregnancy and breast-feeding</strong><br />It is not known if BYETTA may harm your unborn child. Tell your doctor if you are, you think you<br />might be, or are planning to become pregnant as BYETTA should not be used during pregnancy.<br />It is not known if BYETTA passes into your milk. BYETTA should not be used if breast-feeding.<br />Ask your doctor or pharmacist for advice before taking any medicine.<br /><strong>Driving and using machines</strong><br />If you use BYETTA in combination with a sulphonylurea or insulin, low blood sugar (hypoglycaemia)<br />can occur. Hypoglycaemia may reduce your ability to concentrate. Please keep this possible problem<br />in mind in all situations where you might put yourself and others at risk (e.g. driving a car or using<br />machines).<br /><strong>Important information about some of the ingredients of BYETTA</strong><br />This medicine contains less than 1 mmol sodium (23 mg) per dose, i.e. essentially &ldquo;sodium-free&rdquo;.<br />This medicine contains metacresol which may cause allergic reactions.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use BYETTA exactly as your doctor or diabetes nurse has told you. You should check with<br />your doctor, diabetes nurse or pharmacist if you are unsure.<br />Two strengths of BYETTA are available: BYETTA 5 micrograms(&mu;g) and BYETTA<br />10 micrograms(&mu;g). Your doctor may tell you to use BYETTA 5 micrograms(&mu;g) twice a day to start<br />with. After using BYETTA 5 micrograms(&mu;g) twice a day for 30 days the doctor may increase your<br />dose to BYETTA 10 micrograms(&mu;g) twice a day.<br />If you are over 70 years old or have problems with your kidneys it may take longer than 30 days to<br />tolerate the BYETTA 5 micrograms(&mu;g) dose and so your doctor may not increase your dose.<br />One injection of your pre-filled pen will give you your dose. Do not change your dose unless your<br />doctor has told you to.<br />BYETTA should be injected at any time within the 60 minutes (1 hour) before your morning and<br />evening meals, or before your two main meals of the day, which should be about 6 hours or more<br />apart. Do not use BYETTA after your meal.<br />BYETTA is injected under the skin (subcutaneous injection) of your upper leg (thigh), stomach area<br />(abdomen), or upper arm. If you are using BYETTA and an insulin you must make two separate<br />injections.<br />You will not need to test your sugar levels on a day-by-day basis to set the dose of BYETTA.<br />However, if you are also using a sulphonylurea or an insulin your doctor may tell you to check your<br />blood sugar levels to adjust the dose of sulphonylurea or insulin.</p><p><strong>See the accompanying Pen User Manual for instructions for using the BYETTA Pen.</strong><br />Your doctor or nurse must teach you how to inject BYETTA before you use it for the first time.<br />Injection needles are not included. The following are examples of disposable needles that can be used<br />with your BYETTA pen:<br />&bull; 29 (thin), 30 or 31 (thinner) gauge (diameter 0.25 - 0.33mm) and<br />&bull; 12.7, 8 or 5mm length.<br />Ask your doctor or nurse, which needle gauge and length is best for you.<br />Use a new injection needle for each injection and dispose of it after each use. This medicine is for you;<br />never share a BYETTA pen with others.<br /><strong>If you use more BYETTA than you should</strong><br />If you use too much BYETTA you may need medical treatment right away. Too much BYETTA can<br />cause nausea, vomiting, dizziness, or symptoms of low blood sugar.<br /><strong>If you forget to use BYETTA</strong><br />If you miss a dose of BYETTA, skip that dose and take your next dose at the next prescribed time. Do<br />not take an extra dose or increase the amount of your next dose to make up for the one you missed.<br /><strong>If you stop using BYETTA</strong><br />If you feel you should stop using BYETTA consult your doctor. If you stop using BYETTA this can<br />affect your blood sugar levels.<br />If you have any further questions on the use of this medicine, ask your doctor, diabetes nurse or<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, BYETTA can cause side effects although not everybody gets them.<br />Some severe allergic reactions (anaphylaxis) have been reported very rarely (may affect up to 1 in<br />10,000 people).<br />You should see your doctor immediately if you experience symptoms such as<br />&bull; Swollen face, tongue or throat<br />&bull; Difficulty to swallow<br />&bull; Hives and difficulties to breathe</p><p>Cases of inflammation of the pancreas (pancreatitis) have been reported rarely (may affect up to 1 in<br />1,000 people) in patients receiving BYETTA. Pancreatitis can be a serious, potentially life-threatening<br />medical condition.<br />&bull; Tell your doctor if you have had pancreatitis, gallstones, alcoholism or very high triglycerides.<br />These medical conditions can increase your chance of getting pancreatitis, or getting it again,<br />whether or not you are taking BYETTA.<br />&bull; Call your doctor if you experience severe and persistent stomach pain, with or without<br />vomiting, because you could have pancreatitis.<br />Very common side effects of BYETTA (may affect more than 1 in 10 people):<br />&bull; nausea, (nausea is most common when first starting BYETTA, but decreases over time in most<br />patients)<br />&bull; vomiting<br />&bull; diarrhoea<br />&bull; hypoglycaemia<br />When BYETTA is used with a medicine that contains a sulphonylurea or an insulin, episodes of low<br />blood sugar (hypoglycaemia, generally mild to moderate) can occur very commonly. The dose of your<br />sulphonylurea or insulin medicine may need to be reduced while you use BYETTA. The signs and<br />symptoms of low blood sugar may include headache, drowsiness, weakness, dizziness, confusion,<br />irritability, hunger, fast heartbeat, sweating, and feeling jittery. Your doctor should tell you how to<br />treat low blood sugar.<br />Common side effects of BYETTA (may affect up to 1 in 10 people):<br />&bull; dizziness<br />&bull; headache<br />&bull; feeling jittery<br />&bull; pain in the stomach area<br />&bull; bloating<br />&bull; indigestion<br />&bull; increased sweating<br />&bull; loss of energy and strength<br />&bull; heartburn<br />&bull; injection site reactions (redness)<br />&bull; weight decreased<br />&bull; reduced appetite<br />BYETTA may reduce your appetite, the amount of food you eat, and your weight.<br />If you lose weight too quickly (more than 1.5 kg per week) talk to your doctor about it since this may</p><p>not be good for you.<br />Uncommon side effects of BYETTA (may affect up to 1 in 100 people):<br />&bull; unusual taste in the mouth<br />&bull; burping<br />&bull; constipation<br />&bull; gas (flatulence)<br />Rare side effects of BYETTA:<br />&bull; angiodema (swelling of the face and throat)<br />&bull; hypersensitivity (rashes, itching and rapid swelling of the tissues of the neck, face, mouth or<br />throat)<br />&bull; decrease in kidney function<br />&bull; dehydration, sometimes with a decrease in kidney function<br />&bull; drowsiness<br />&bull; hair loss<br />In addition some other side effects have been reported (frequency not known, cannot be estimated<br />from the available data).<br />&bull; Changes in INR (measurement of blood thinning) have been reported when used together with<br />warfarin.<br />If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please<br />tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />Do not use BYETTA after the expiry date which is stated on the label and the carton after &lsquo;EXP&rsquo;. The<br />expiry date refers to the last day of that month.<br />Store in a refrigerator (2 &deg;C &ndash; 8 &ordm;C). Return pen to refrigerator after each use.<br />Replace the cap on the pen in order to protect from light. Do not freeze. Throw away any BYETTA<br />pen that has been frozen.</p><p>Use a BYETTA pen for only 30 days. Dispose of a used BYETTA pen after 30 days, even if some<br />medicine remains in the pen.<br />Do not use BYETTA if you notice particles in the solution, or if it is cloudy or coloured.<br />Do not store the BYETTA pen with the needle attached. If the needle is left on, medicine may leak<br />from the BYETTA pen or air bubbles may form in the cartridge.<br />Medicines should not be disposed of via waste water or household waste. Ask your pharmacist how to<br />dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is exenatide.<br />- Two pre-filled pens are available. One to deliver doses of 5 micrograms (&mu;g) and one<br />10 micrograms (&mu;g).<br />- Each dose of BYETTA 5 micrograms (&mu;g) solution for injection (injection) contains<br />5 micrograms (&mu;g) exenatide in 20 microlitre.<br />- Each dose of BYETTA 10 micrograms (&mu;g) solution for injection (injection) contains<br />10 micrograms (&mu;g) exenatide in 40 microlitre.<br />- Each millilitre (ml) of the solution for injection contains 0.25 milligrams (mg) of exenatide.<br />- The other ingredients are metacresol, (44 micrograms/dose in BYETTA 5 micrograms(&mu;g)<br />solution for injection and 88 micrograms/dose in BYETTA 10 micrograms(&mu;g) solution for<br />injection), mannitol, glacial acetic acid, sodium acetate trihydrate and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                BYETTA is a clear and colourless liquid (solution for injection) filled in a glass cartridge within a pen.
When the pen is empty, you cannot use it again. Each pen has 60 doses to provide 30 days of twice–a–
day injections.
It is available in pack sizes of 1 and 3 pens. Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufacturer of the Dosage Form<br />Baxter Pharmaceutical Solutions LLC<br />927 South CurryPike<br />Bloomington, Indiana 47403<br />USA<br />Packaging and Labeling Facility<br />Enestia Belgium nv<br />Klocknerstraat 1,<br />Hamont-Achel, B-3930,<br />Belgium</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July 2014
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>&nbsp;</p><p>عقار باييتا يحتوي على المادة الفعالة إكزيناتايد والذي يستخدم لتحسين التحكم في مستوى السكر في الدم</p><p>في البالغين الذين يعانون من النوع الثاني من داء السكري )الذي لا يعتمد على الأنسولين(</p><p>يستخدم عقار باييتا مع أدوية السكر الأخرى مثل ميتفورمين ستالفونيل يوريتا أو ثيازوليدينيتديون و Basal و</p><p>الانسولين طويل المفعول.</p><p>يستطيع طبيبك الآن ان يصف لك عقار باييتا كدواء إضافي للمساعدة في التحكم في مستوى السكر في الدم</p><p>عليك متابعة الاستمرار في نظامك الغذائي وممارسة الرياضة .</p><p>سبب إصابتك بداء السكري هو عدم تصنيع جسمك الانسولين الكافي ليتحكم في مستوى السكر في التدم أو</p><p>ان جسمك لا يستخدم الانسولين مشكل صحيح .</p><p>يقوم عقار باييتا بمساعدة جسمك في زيادة إنتاج الانسولين عندما يكون مستوى السكر في الدم مرتفعا .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>لا تستخدم باييتا في الحالة التالية :</p><p>- إذا كنت تعاني من حساسية )حساسية مفرطة( لمادة إكزيناتايد أو أي مكون آختر متن مكونتات</p><p>باييتا المدونة في نهاية هذه النشرة .</p><p><strong>ما عليك مراعاته أثناء استخدام عقار باييتا :</strong></p><p>&nbsp;</p><p>- عند الجمع بينه وبين سالفونيل يوريا وذلك لإمكانية حدوث انخفاض في مستوى الستكر فتي التدم .</p><p>اسأل طبيبك المعالج أو الصتيدلي إن لتم تكتن متأكتدا إن كتان أحتد ادويتتك الأخترى يحتتوي علتى</p><p>سالفونيل يوريا.</p><p>- يجب عدم استخدام باييتا إذا كنت تعاني من النوع الأول من الداء السكري أو الحماض الكيتتوني</p><p>السكري )والتي تعتبر حالة خطيرة يمكن أن تحدث في مرضى الداء السكري(</p><p>- يجب حقن باييتا تحت الجلد وليس بداخل الوريد أو العضلات.</p><p>- إن كانت لديك مشكلات شديدة فتي الإفترا المعتدي ) ويشتمل ذلتك شتلل جزئتي فتي القنتاة</p><p>الهضمية ( أو هضم الطعام فإن استخدام باييتا في هذه الحالة غير مستحب . باييتا يبطيء من</p><p>الإفرا المعدي لذلك فان الطعام يمر ببطء أكثر خلال معدتك.</p><p>- أخبر الطبيب إذا كنت قد عانيت من التهاب في البنكرياس سابقًا )التهاب البنكرياس( )انظر القسم</p><p>.)4</p><p>- ليس هناك سوى القليل من التجارب على باييتا في المرضى الذين يقل مؤشر كتلة الجسم)IMB(</p><p>لهم عن 25 أو يساويها.</p><p>- ليس هناك سوى القليل من التجارب على باييتا فتي المرضتى التذين يعتانون متن مشتكلات فتي</p><p>الكلى. لا يوصى باستخدام باييتا إذا كنت تعاني من مرض حاد فتي الكلتى أو كنتت تأختذ جلستات</p><p>غسيل كلوي.</p><p><strong>الأطفال والمراهقون</strong></p><p>لا يوجد تجارب على باييتا في الأطفال والمراهقون تحت 18.&nbsp;سنة ولذا لا يُوصى باستخدام بايتا في هذه الفئتة</p><p>العمرية.</p><p><strong>استخدام الأدوية الأخرى :</strong></p><p>إن كنت تأخذ أو أخذت مؤخرا أي أدوية أخرى - بما في ذلك الأدوية التي حصلت عليها بدون وصفة طبية)علتى</p><p>سبيل المثال الوارفارين( - فضلا اخبر طبيبك أو الصيدلي</p><p>أستشر طبيبك المعالج عما إذا كان موعد تناول أي دواء آخر تأخذه بحاجة إلى التغيير حيث إن باييتا يبطئ</p><p>إفرا المعدة، فإنه يمكن أن يؤثر على الأدوية التي تحتاج إلى المرور عبر المعدة بسرعة.</p><p>الأقراص أو الكبسولات المقاومة للمعدة )مثل مثبطات مضخة البروتون( التي يجب ألا تبقى طويلا جدًا في</p><p>المعدة ينبغي تناولها قبل تناول بايتا بساعة أو بعده بت 4 ساعات.</p><p>هناك بعض المضادات الحيوية التي ينبغي تناولها قبل حقن بايتا بساعة.</p><p>بالنسبة إلى الأقراص التي تحتاج إلى تناولها مع الطعام ربما يكون من الأفضل تناولها مع وجبة في وقت لا</p><p>تتناول فيه بايتا.</p><p>لا يوصى باستخدام بايتا مع الأدوية الأخرى المستخدمة لعلاج النوع الثاني من الداء السكري والتي تعمل</p><p>بالطريقة نفسها التي يعمل بها الدواء بايتا )مثل: ليراجلوتيد وبايدوريون ]اكسيناتيد مرة واحدة في الأسبوع[(.</p><p><strong>استخدام عقار باييتا مع الطعام والشراب :</strong></p><p>استخدم باييتا في أي وقت خلال الت 6١ دقيقتة ٠ستاعة( قبتل ( وجبتتك . ) أنظتر 3 كيفيتة استتخدام باييتتا( . لا</p><p>تستخدم باييتا بعد تناول الوجبات .</p><p><strong>الحمل والرضاعة :</strong></p><p>من غير المعروف إن كان عقار باييتا يضر بالجنين . أخبري طبيبك إن كنت حاملا أو تعتقدين أنك حامتل أو إن</p><p>كنت تخططين لذلك حيث أن باييتا لا يجب استعماله أثناء الحمل .</p><p>من غير المعروف إن كان باييتا يمر إلى لبن الأم . لا يجب استخدام باييتا أثناء الرضاعة الطبيعية .</p><p>استشيري طبيبك أو الصيدلي قبل تناول أي دواء</p><p>&nbsp;</p><p><strong>القيادة وتشغيل الآلات</strong></p><p>إذا كنت تستخدم باييتا مع سولفونيل يوريا فقد يحدث هبوط في مستوى السكر في الدم . يؤدي نقص السكر</p><p>في الدم إلى عدم قدرتك على التركيز . ضع دوما هذه الاحتمالية في الحسبان في كل المواقف التي قد تضع</p><p>نفسك والآخرين فيها في أي مخاطرة ) مثل قيادة السيارة أو تشغيل الآلات ( .</p><p><strong>معلومات مهمة بشأن بعض مكونات عقار باييتا :</strong></p><p>هذا الدواء يحتوي على اقل من ٠ ممول صوديوم) 23 جرام( في الجرعة أي الصوديوم الحر الأساسي .</p><p>هذا الدواء يحتوي على ميتاكريسول والتي قد تسبب الحساسية</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>استخدم عقار باييتا دوما كما أخبرك طبيبك أو مثقفة السكري بالضتبط . عليتك مراجعتة طبيبتك أو الصتيدلي أو</p><p>المثقفة إن كنت غير واثقا .</p><p>يتوافر عقار باييتا في هيئتين : باييتا 5 مايكرو جرام و باييتا 10مايكرو جرام. قد يخبرك طبيبتك إن تستتعمل 5</p><p>مايكرو جرام مرتين يوميا لبدء العلاج به و بعد استخدام باييتا ٥ مايكرو جرام مرتين يوميتا لمتدة 3١ يتوم قتد</p><p>يزيد طبيبك الجرعة إلى 10 مايكروجرام مرتين يوميا .</p><p>إذا كان عمرك أكبر من 10 سنة أو كنت تعاني من مشكلات في الكلى فقتد تزيتد متدة تحملتك لجرعتة بايتتا ٥</p><p>مايكروجرام عن30 يومًا ولذا قد لا يحتاج الطبيب إلى زيادة جرعتك.</p><p>حقنة واحدة من القلم المملوء مسبقا ستعطيك جرعتك. لا تغير جرعتك إلا إذا أخبرك طبيبك بذلك .</p><p>يجب حقن عقار باييتا في أي وقت خلال 60 دقيقة 1 ساعة ( ( قبل وجبتي الصباح والمساء أو قبل التوجبتين</p><p>الرئيسيتين في اليوم على أن يكون الوقت الفاصل بينهما 6 ساعات أو أكثر .لا تستخدم باييتا بعد الوجبات .</p><p>يحقن عقار باييتا تحت الجلد في الجزء العلوي من الساق )الفخذ( في منطقة المعدة ) البطن( أو الجزء</p><p>العلوي من الذراع. إذا كنت تستخدم حقن باييتا وحقن أنسولين، فيجب الفصل بين الحقنتين.</p><p>لا تحتاج لقياس مستوى السكر في الدم يوميا لمعرفة جرعة باييتا . ولكن إن كنت تتناول أيضًا سلفونيل يوريا أو</p><p>الأنسولين فقد يجعلك طبيبك تجري اختبار لفحص مستوى السكر بالدم لتتمكن من ضبط جرعة السلفونيل</p><p>يوريا أو الأنسولين .</p><p>انظر أيضًا في الدليل المرفق لتعليمات استخدام القلم لمعرفة كيفية استخدام قلم باييتا.</p><p>سيقوم طبيبك أو مثقفة السكري بتعليمك كيف تحقن نفسك بعقار باييتا قبل أن تستخدمه للمرة الأولى.</p><p>إبر الحقن غير مشمولة. والأنواع الآتية لإبر تكون للاستخدام لمرة واحدة يمكن استخدامها مع قلم باييتا :</p><ul><li>عيار 29 ) رفيع (و 3١ أو 3٠ )أرفع()قطر 0،25- 0،33مم)</li><li>7،12 او 5 مم طول</li></ul><p>&nbsp;</p><p>اسأل الطبيب أو مثقفة السكري عن العيار والطول الأفضل لك .</p><p>استخدم إبرة جديدة في كل مرة وتخلص منها بعد كل استخدام . هذا الدواء لك أنت لا تشارك قلم باييتا أبتدًا</p><p>مع الآخرين .</p><p>إذا استخدمت جرعة من عقار باييتا اكثر مما ينبغي :</p><p>ستحتاج علاج طبي على الفور إذا أخذت جرعة باييتا أكثر مما يجب .</p><p>قد يسبب ذلك غثيان قيء دوار أو أعراض انخفاض مستوى السكر في الدم .</p><p>إذا نسيت استخدام عقار باييتا :</p><p>&nbsp;</p><p>إذا فاتك جرعة عقار باييتا تخطى هذه الجرعة وتناول جرعتك التالية في الوقت الموصوف لها . لا تأخذ جرعة</p><p>اكبر أو تزيد من الجرعة التالية لتعويض الجرعة الفائتة .</p><p>إذا توقفت عن استخدام عقار باييتا :</p><p>إذا شعرت أن عليك التوقف عن استخدام عقار باييتا استشر طبيبك أولا . إذا توقفت عن استخدام عقار باييتتا</p><p>قد يؤثر ذلك على مستوى السكر في دمك .</p><p>إذا كانت لديك أي أسئلة إضافية بشأن استخدام الدواء اسأل طبيبك المعالج أو مثقفة السكري أو الصيدلي .</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>كسائر الأدوية عقار باييتا له بعض الآثار الجانبية بالرغم من أنها لا تحدث مع الجميع</p><p>تم الإبلا عن بعض ردود الأفعال التحسسية الشديدة )تأ ق ( في حالات نادرة جدًا )يمكن أن تؤثر في ما يصل</p><p>إلى شخص واحد من كل 10000 شخص(.</p><p>يجب الذهاب إلى الطبيب على الفور إذا حدثت لك أعراض مثل:</p><p>&bull; تورم الوجه أو اللسان أو الحلق</p><p>&bull; صعوبة البلع</p><p>&bull; صعوبات في التنفس</p><p>تم الإبلا عن حالات من التهاب البنكرياس بشكل نادر )يمكن أن تؤثر في ما يصل إلى شخص واحد من كل</p><p>1000 شخص( في المرضى الذين يستخدمون بايتا.يمكن أن يكون التهاب البنكرياس حالة مرضية خطيرة</p><p>وتمثل تهديد محتملا للحياة.</p><p>&bull; أخبر الطبيب إذا كنت عانيت من التهاب في البنكرياس أو حصوات مرارية أو إدمان الكحول أو ارتفاع شديد</p><p>في ثلاثي الجليسريد سابقًا.</p><p>يمكن أن تزيد هذه الحالات الطبية من فرصة إصابتك بالتهاب البنكرياس أو عودته إليك مرة أخرى، وذلك سواء</p><p>أكنت تستخدم بايتا أم لا.</p><p>&bull; اتصل بالطبيب إذا شعرت بألم حاد ومستمر في المعدة، سواء أكان مصتحوبًا بقتيء أم لا لأنتك قتد تُصتاب</p><p>بالتهاب البنكرياس.</p><p>التأثيرات الشائعة جدا للباييتا قد تؤثر في أكثر من 1 في كل 10 مرضى ظهر لديهم :</p><p>-غثيان )الغثيان هو الأكثر شيوعا عند اخذ الجرعة الأولى من عقار باييتا ولكنه يقل بمرور الوقت عند معظم</p><p>المرضى )</p><p>- قيء</p><p>-إسهال</p><p>-انخفاض السكر في الدم</p><p>قد يؤدي استخدام عقار باييتا مع الأدوية التي تحتوي على سولفونيل يوريا أو الأنسولين إلتى حتدوث نوبتات</p><p>من انخفاض السكر في الدم )عادة ما تكون بسيطة إلى متوسطة( وتتكرر بشكل شائع.</p><p>قد تحتاج إلى إنقاص جرعة دوائك من السلفونيل يوريا أو الأنسولين أثناء استخدامك عقار باييتا .</p><p>علامات وأعراض انخفاض مستوى السكر في الدم تشمل : صداع- دوخة- ضعف - نعتاس - ارتبتاك &ndash; تهتيج-</p><p>جوع- تسارع ضربات القلب- تعرق- الشعور بالعصبية . يجب أن يخبرك طبيبك عن كيفية التعامل مع انخفتاض</p><p>السكر في الدم .</p><p>التأثيرات الشائعة : اقل من ٠ في كل ٠١ ولكن اكثر من ٠ في كل ٠١١ مريض :</p><ul><li>&nbsp;نعاس</li><li>&nbsp;صداع</li><li>&nbsp;الشعور بالعصبية</li><li>الم في منطقة المعدة</li><li>&nbsp;انتفاخ</li><li>&nbsp;عسر هضم</li><li>&nbsp;زيادة التعرق</li><li>&nbsp;فقدان الطاقة والقوة</li><li>&nbsp;حموضة</li><li>&nbsp;تفاعل في مكان الحقن )احمرار(.</li><li>&nbsp;انخفاض الوزن</li><li>&nbsp;انخفاض الشهية</li></ul><p>قد يقلل باييتا من شهيتك وكمية الطعام التي تتناوله ومن ثم نقصان وزنك.<br />إذا فقدت وزنك بسرعة شديدة )أكثر من 1،5&nbsp;كجم في الأسبوع( فأخبر الطبيب بذلك لأن ذلك قد لا يكون شيئًا<br />حسنًا بالنسبة لك.<br /><strong>الآثار الجانبية غير الشائعة لباييتا )</strong>يمكن أن تؤثر في ما يصل إلى شخص واحد من كل100شخص(:<br />&bull; طعم غير معتاد في الفم<br />&bull; تجشؤ<br />&bull; إمساك<br />&bull; غازات )انتفاخ(<br /><strong>الآثار الجانبية النادرة لباييتا:</strong><br />&bull; وذمة وعائية)تورم الوجه والحلق(<br />&bull; حساسية مفرطة)طفح جلدي- حكة- وتورم سريع في أنسجة الرقبة أو الوجه أو الفم أو الحلق(<br />&bull; انخفاض في وظائف الكلى<br />&bull; جفاف، وأحيانًا مع انخفاض في وظائف الكلى<br />&bull; نعاس<br />&bull; سقوط الشعر<br />إضافةً إلى ذلك تم الإبلا عن بعض الآثار الجانبية الأخرى )غير معلوم مدى تكرارها ولا يمكن تقديرها من<br />البيانات المتوفرة(.<br />مقياس تخثر الدم( عند الاستخدام مع وارفارين. ( BNI &bull; تم الإبلا عن تغيرات في مقياس<br />إذا زادت خطورة أي من الآثار الجانبية أو إذا لاحظت حدوث أي آثار جانبية غير المذكورة في هذه النشرة<br />فيُرجى إخبار الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>احفظ الدواء بعيدا عن متناول و رؤية الأطفال.</p><p>لا تستخدم عقار باييتا بعد تاريخ انتهاء الصلاحية الموجود على العلبة . تاريخ الانتهاء يشير إلى اخر يوم في من</p><p>ذلك الشهر.</p><p>يحفظ في الثلاجة(2-8)&nbsp; درجة مئوية .أعد القلم إلى الثلاجة بعد كل استعمال.&nbsp;</p><p>ضع الغطاء على القلم لحمايته من الضوء . لا تجمده وتخلص من أي قلم باييتا تم تجميده.</p><p>استخدم قلم باييتا لمدة 30 يوما فقط . تخلص من القلم المستتخدم بعتد 30 يومتا حتتى وإن تبقتى بته بعتض</p><p>الدواء .</p><p>لا تستخدم قلم باييتا إن لاحظت وجود شوائب في المحلول أو إن كان معكرا أو ملونا .</p><p>لا تحفظ قلم باييتا بينما هو متصل بالإبرة. إذا حدث ذلك فقد يؤدي إلتى تستريب التدواء متن القلتم أو تكتون</p><p>فقاعات هوائية في الخرطوشة .</p><p>يجب عدم التخلص من الأدوية في مياه الصرف أو المياه المنزلية . اسأل طبيبك عن كيفية التخلص من الأدوية<br />التي لم تعد تستخدمها . تساعد هذه الإجراءات في حماية البيئة</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;</p><p>أقلام باييتا المملوءة مسبقا متوفرة بشتكلين أحتدهما يقتدم جرعتة ٥ متايكرو جترام والآختر ٠١</p><p>مايكرو جرام.</p><p>- كل جرعة من عقار باييتا ٥ مايكروجرام للحقتن يحتتوي علتى ٥ متايكرو جترام إكزيناتايتد فتي</p><p>2١ ميكروليتر.</p><p>- كل جرعة من عقار باييتا ٠١ مايكروجرام للحقن يحتوي على 10مايكرو جرام إكزيناتايد فتي</p><p>40 ميكروليتر.</p><p>- كل ميليليتر ) مل ( من محلول الحقن يحتوي على 0,25&nbsp;مليجرام )مج ( من إكزيناتايد.</p><p>- المكونات الأخرى هي ميتاكريسول ) 44 متايكروجرام / جرعتة فتي عقتار باييتتا ٥ متايكروجرام</p><p>للحقتن و 88متايكرو جترام / جرعتة فتي عقتار باييتتا ٠١ متايكروجرام للحقتن ( متانيتول حمتض</p><p>جلاشيال اسيتيك اسيتات الصوديوم ثلاثية التميوء وماء للحقن .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            عقار باييتا صافي وعديم اللون ومملوء في خرطوشة زجاجية بداخل القلم .
عندما يفر القلم لا تستخدمه مرة أخرى .في كل قلم 60 جرعة لتغطي 30 يوما على أساس الحقن مرتين
في اليوم .
العبوة متوفرة بحجم 1 و 3 أقلام .قد لا تكون كل أحجام العبوات مطروحة في السوق.
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>تم التصنيع في:<br />Baxter Pharmaceutical Solutions LLC<br />927 South CurryPike<br />Bloomington, Indiana 47403<br />USA<br />تم تعبئته بواسطة:<br />Enestia Belgium nv<br />Klocknerstraat 1,<br />Hamont-Achel, B-3930,<br />Belgium</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
             يوليو 2014
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                BYETTA 5 micrograms solution for injection, prefilled pen
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each dose contains 5 micrograms (μg) exenatide in 20 microlitres(μl), (0.25 mg exenatide per ml).
Excipients:
Each dose contains 44 μg metacresol.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection (injection), pre-filled pen.
Clear, colourless solution.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>BYETTA is indicated for treatment of type 2 diabetes mellitus in combination with:<br />- metformin<br />- sulphonylureas<br />- thiazolidinediones<br />- metformin and a sulphonylurea<br />- metformin and a thiazolidinedione<br />in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these<br />oral therapies.<br />BYETTA is also indicated as adjunctive therapy to basal insulin with or without metformin and/or<br />pioglitazone in adults who have not achieved adequate glycaemic control with these agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u><br />BYETTA therapy should be initiated at 5 &mu;g exenatide per dose administered twice daily (BID) for at<br />least one month in order to improve tolerability. The dose of exenatide can then be increased to 10 &mu;g<br />BID to further improve glycaemic control. Doses higher than 10 &mu;g BID are not recommended.<br />BYETTA is available as either a 5 &mu;g or a 10 &mu;g exenatide per dose pre-filled pen.<br />BYETTA can be administered at any time within the 60-minute period before the morning and<br />evening meal (or two main meals of the day, approximately 6 hours or more apart). BYETTA should<br />not be administered after a meal. If an injection is missed, the treatment should be continued with the<br />next scheduled dose.<br />BYETTA is recommended for use in patients with type 2 diabetes mellitus who are already receiving<br />metformin, a sulphonylurea, pioglitazone and/or a basal insulin. One can continue to use BYETTA<br />when a basal insulin is added to existing therapy. When BYETTA is added to existing metformin<br />and/or pioglitazone therapy, the current dose of metformin and/or pioglitazone can be continued as no<br />increased risk of hypoglycaemia is anticipated, compared to metformin or pioglitazone alone. When</p><p>BYETTA is added to sulphonylurea therapy, a reduction in the dose of sulphonylurea should be<br />considered to reduce the risk of hypoglycaemia (see section 4.4.). When BYETTA is used in<br />combination with basal insulin, the dose of basal insulin should be evaluated. In patients at increased<br />risk of hypoglycaemia consider reducing the dose of basal insulin (see section 4.8).<br />The dose of BYETTA does not need to be adjusted on a day-by-day basis depending on selfmonitored<br />glycaemia. However, blood glucose self-monitoring may become necessary to adjust the<br />dose of sulphonylureas or the dose of basal insulin.<br /><u>Specialpopulations</u><br />Elderly<br />BYETTA should be used with caution and dose escalation from 5 &mu;g to 10 &mu;g should proceed<br />conservatively in patients &gt;70 years. The clinical experience in patients &gt;75 years is very limited.<br /><em>Patients with renal impairment</em><br />No dosage adjustment of BYETTA is necessary in patients with mild renal impairment (creatinine<br />clearance 50 &ndash; 80 ml/min).<br />In patients with moderate renal impairment (creatinine clearance:30-50 ml/min), dose escalation from<br />5 &mu;g to 10 &mu;g should proceed conservatively (see section 5.2).<br />BYETTA is not recommended for use in patients with end-stage renal disease or severe renal<br />impairment (creatinine clearance &lt;30 ml/min) (see section 4.4).<br /><em>Patients with hepatic impairment</em><br />No dosage adjustment of BYETTA is necessary in patients with hepatic impairment (see section 5.2).<br /><em>Paediatric population</em><br />The safety and effectiveness of exenatide have not been established in patients under 18 years of age.<br />(see section 5.2).<br />Currently available data are described in section 5.2 but no recommendation on a posology can be<br />made.</p><p><u>Method of administration</u><br />Each dose should be administered as a subcutaneous injection in the thigh, abdomen, or upper arm.<br />BYETTA and basal insulin must be administered as two separate injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>BYETTA should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic<br />ketoacidosis.<br />BYETTA must not be administered by intravenous or intramuscular injection.<br /><u>Renal impairment</u><br />In patients with end-stage renal disease receiving dialysis, single doses of BYETTA 5 &mu;g increased<br />frequency and severity of gastrointestinal adverse reactions. BYETTA is not recommended for use in<br />patients with end-stage renal disease or severe renal impairment (creatinine clearance &lt;30 ml/min).<br />The clinical experience in patients with moderate renal impairment is very limited (see section 4.2).</p><p>There have been rare, spontaneously reported events of altered renal function, including increased<br />serum creatinine, renal impairment, worsened chronic renal failure and acute renal failure, sometimes<br />requiring hemodialysis. Some of these events occurred in patients experiencing events that may affect<br />hydration, including nausea, vomiting, and/or diarrhoea and/or receiving medicinal products known to<br />affect renal function/hydration status. Concomitant medicinal products included angiotensin<br />converting enzymes inhibitors, angiotensin-II antagonists, nonsteroidal anti-inflammatory medicinal<br />products and diuretics. Reversibility of altered renal function has been observed with supportive<br />treatment and discontinuation of potentially causative medicinal products, including BYETTA.<br /><u>Severe gastrointestinal disease</u><br />BYETTA has not been studied in patients with severe gastrointestinal disease, including gastroparesis.<br />Its use is commonly associated with gastrointestinal adverse reactions, including nausea, vomiting,<br />and diarrhoea. Therefore, the use of BYETTA is not recommended in patients with severe<br />gastrointestinal disease.<br /><u>Acute pancreatitis</u><br />There have been rare, spontaneously reported events of acute pancreatitis. Patients should be informed<br />of the characteristic symptom of acute pancreatitis: persistent, severe abdominal pain. Resolution of<br />pancreatitis has been observed with supportive treatment but very rare cases of necrotising or<br />hemorrhagic pancreatitis and/or death have been reported. If pancreatitis is suspected, BYETTA and<br />other potentially suspect medicinal products should be discontinued. Treatment with BYETTA should<br />not be resumed after pancreatitis has been diagnosed.<br /><u>Concomitant medicinal products</u><br />The effect of BYETTA to slow gastric emptying may reduce the extent and rate of absorption of orally<br />administered medicinal products. BYETTA should be used with caution in patients receiving oral<br />medicinal products that require rapid gastrointestinal absorption and medicinal products with a narrow<br />therapeutic ratio. Specific recommendations regarding intake of such medicinal products in relation to<br />BYETTA is given in section 4.5.<br />The concurrent use of BYETTA with D-phenylalanine derivatives (meglitinides), alpha-glucosidase<br />inhibitors, dipeptidyl peptidase-4 inhibitors or other GLP-1 receptor agonists has not been studied and<br />cannot be recommended.</p><p><u>Patients with BMI &le;25</u><br />The experience in patients with BMI &le;25 is limited.<br /><u>Rapid weight loss</u><br />Weight loss greater than 1.5 kg per week has been observed in approximately 5 % of clinical trial<br />patients treated with exenatide. Weight loss of this rate may have harmful consequences.<br /><u>Hypoglycaemia</u><br />When BYETTA was used in combination with a sulphonylurea, the incidence of hypoglycaemia was<br />increased over that of placebo in combination with a sulphonylurea. In the clinical studies patients on<br />a sulphonylurea combination, with mild renal impairment had an increased incidence of<br />hypoglycaemia compared to patients with normal renal function. To reduce the risk of hypoglycaemia<br />associated with the use of a sulphonylurea, reduction in the dose of sulphonylurea should be<br />considered.<br /><u>Excipients</u><br />This medicinal product contains less than 1 mmol sodium per dose, i.e. essentially &ldquo;sodium-free&rdquo;.<br />This medicinal product contains metacresol, which may cause allergic reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The effect of BYETTA to slow gastric emptying may reduce the extent and rate of absorption of orally<br />administered medicinal products. Patients receiving medicinal products of either a narrow therapeutic<br />ratio or medicinal products that require careful clinical monitoring should be followed closely. These<br />medicinal products should be taken in a standardised way in relation to BYETTA injection. If such<br />medicinal products are to be administered with food, patients should be advised to, if possible, take<br />them with a meal when BYETTA is not administered.<br />For oral medicinal products that are particularly dependent on threshold concentrations for efficacy,<br />such as antibiotics, patients should be advised to take those medicinal products at least 1 hour before<br />BYETTA injection.<br />Gastroresistant formulations containing substances sensitive for degradation in the stomach, such as<br />proton pump inhibitors, should be taken at least 1 hour before or more than 4 hours after BYETTA<br />injection.<br /><u>Digoxin, lisinopril and warfarin</u><br />A delay in tmax of about 2 h was observed when digoxin, lisinopril or warfarin was administered<br />30 min after exenatide. No clinically relevant effects on Cmax or AUC were observed. However, since<br />market introduction, increased INR (International Normalized Ratio) has been reported during<br />concomitant use of warfarin and BYETTA. INR should be closely monitored during initiation and<br />dose increase of BYETTA therapy in patients on warfarin and/or cumarol derivatives (see section 4.8).<br /><u>Metformin or sulphonylureas</u><br />BYETTA is not expected to have any clinically relevant effects on the pharmacokinetics of metformin<br />or sulphonylureas. Hence no restriction in timing of intake of these medicinal products in relation to<br />BYETTA injection are needed.<br /><u>Paracetamol</u><br />Paracetamol was used as a model medicinal product to evaluate the effect of exenatide on gastric<br />emptying. When 1000 mg paracetamol was given with 10 &mu;g BYETTA (0 h) and 1 h, 2 h and 4 h after<br />BYETTA injection, paracetamol AUCs were decreased by 21 %, 23 %, 24 % and 14 % respectively;<br />Cmax was decreased by 37 %, 56 %, 54 % and 41 %, respectively; tmax was increased from 0.6 h in the<br />control period to 0.9 h, 4.2 h, 3.3 h, and 1.6 h, respectively. Paracetamol AUC, Cmax and tmax were not<br />significantly changed when paracetamol was given 1 hour before BYETTA injection. No adjustment<br />to paracetamol dosing is required based on these study results.<br /><u>Hydroxy Methyl Glutaryl Coenzyme A (HMG CoA) reductase inhibitors</u><br />Lovastatin AUC and Cmax were decreased approximately 40 % and 28 %, respectively, and Tmax was<br />delayed about 4 h when BYETTA (10 &mu;g BID) was administered concomitantly with a single dose of<br />lovastatin (40 mg) compared with lovastatin administered alone. In the 30-week placebo-controlled<br />clinical trials, concomitant use of BYETTA and HMG CoA reductase inhibitors was not associated<br />with consistent changes in lipid profiles (see section 5.1). Although no predetermined dose adjustment<br />is required, one should be aware of possible changes in LDL-C or total cholesterol. Lipid profiles<br />should be monitored regularly.</p><p><u>Ethinyl estradiol and levonorgestrel</u><br />Administration of a combination oral contraceptive (30 &mu;g ethinyl estradiol plus 150 &mu;g<br />levonorgestrel) one hour before BYETTA (10 &mu;g BID) did not alter the AUC, C<sub>max</sub> or C<sub>min</sub> of either<br />ethinyl estradiol or levonorgestrel. Administration of the oral contraceptive 30 minutes after BYETTA<br />did not affect AUC but resulted in a reduction of the C<sub>max</sub> of ethinyl estradiol by 45 %, and C<sub>max </sub>of<br />levonorgestrel by 27-41 %, and a delay in tmax by 2-4 h due to delayed gastric emptying. The reduction<br />in C<sub>max</sub> is of limited clinical relevance and no adjustment of dosing of oral contraceptives is required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential</u><br />If a patient wishes to become pregnant, or pregnancy occurs, treatment with BYETTA should be<br />discontinued.<br /><u>Pregnancy</u><br />There are no adequate data from the use of BYETTA in pregnant women. Studies in animals have<br />shown reproductive toxicity (see section 5.3). The potential risk for humans is unknown. BYETTA<br />should not be used during pregnancy and the use of insulin is recommended.<br /><u>Breastfeeding</u><br />It is unknown whether exenatide is excreted in human milk. BYETTA should not be used if breast<br />feeding.<br /><u>Fertility</u><br />No fertility studies in humans have been conducted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been performed. When<br />BYETTA is used in combination with a sulphonylurea or a basal insulin, patients should be advised to<br />take precautions to avoid hypoglycaemia while driving and using machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u><br />The most frequent adverse reactions were mainly gastrointestinal related (nausea, vomiting and<br />diarrhoea). The most frequently reported single adverse reaction was nausea which was associated<br />with the initiation of treatment and decreased over time. Patients may experience hypoglycaemia when<br />BYETTA is used with a sulphonylurea. Most adverse reactions associated with BYETTA were mild to<br />moderate in intensity.<br />Acute pancreatitis and acute renal failure have been reported rarely since exenatide twice daily has<br />been marketed (see section 4.4).<br /><u>Tabulated list of adverse reactions</u><br />Table 1 lists adverse reactions reported from Phase 3 studies. The table presents adverse reactions that<br />occurred with an incidence &ge;5 % and more frequently among BYETTA-treated patients than insulinor<br />placebo-treated patients. The table also includes adverse reactions that occurred with an incidence<br />&ge;1 % and with a statistically significantly higher and/or &ge;2X incidence among BYETTA-treated<br />patients than insulin- or placebo-treated patients.<br />The reactions are listed below as MedDRA preferred term by system organ class and absolute<br />frequency. Patient frequencies are defined as: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10),<br />uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), very rare (&lt;1/10,000) and not known<br />(cannot be estimated from the available data), including isolated reports.</p><p>&nbsp;</p><p><u>T</u><u>able 1: Adverse reactions reported in long term phase 3 controlled studies</u><u>1 </u><u>and spontaneous adverse</u> <u>reactions</u><u>3</u></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p><p><strong>/adverse reaction terms</strong></p></td><td colspan="6" style="vertical-align:top"><p><strong>F</strong><strong>r</strong><strong>equency of occurrence</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Common</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>not known</p></td></tr><tr><td style="vertical-align:top"><p><strong>Immune system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Anaphylactic reaction</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Metabolism and nutrition disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypoglycaemia (with metformin and a sulphonylurea) 2</p></td><td style="vertical-align:top"><p>X1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hypoglycaemia (with a sulphonylurea)</p></td><td style="vertical-align:top"><p>X1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Decreased appetite</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dehydration, generally</p><p>associated with nausea, vomiting and/or</p><p>diarrhoea.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>N</strong><strong>ervous system disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Headache 2</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dysgeusia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>G</strong><strong>astrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>X1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>X1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>X1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Gastroesophageal reflux disease</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Abdominal distension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Acute pancreatitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Eructation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Flatulence</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Hyperhidrosis 2</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Alopecia</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Macular and papular rash</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus, and/ or urticaria</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Angioneurotic oedema</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Renal and urinary disorders</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Altered renal function,</p><p>including acute renal failure, worsened chronic</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>renal failure, renal impairment, increased serum creatinine</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>G</strong><strong>eneral disorders and administration site conditions</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Feeling jittery</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Asthenia 2</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Injection site reactions</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X1,3</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X1</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>International normalised ratio increased with concomitant warfarin, some reports associated with bleeding</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>X</p></td></tr></tbody></table><p>1 Data from Phase 3 comparator-controlled studies versus placebo, insulin glargine or 30 % soluble insulin aspart/ 70 % insulin aspart protamine crystals (biphasic insulin aspart) in which patients also received metformin, thiazolidinediones or sulphonylurea in addition to BYETTA or comparator.</p><p>(N= 1788 BYETTA-treated intent-to-treat (ITT) patients.)</p><p>&nbsp;</p><p>2 In insulin-comparator controlled studies in which metformin and a sulphonylurea were concomitant medicinal products, the incidence for these adverse reactions was similar for insulin- and BYETTA- treated patients.</p><p>&nbsp;</p><p>3 Post marketing reports</p><p>&nbsp;</p><p>When BYETTA was used in combination with basal insulin therapy the incidence and types of other adverse events observed were similar to those seen in the controlled clinical trials with exenatide as monotherapy, with metformin and/or sulphonylurea or a thiazolidinedione, with or without metformin.</p><p>&nbsp;</p><p><u>D</u><u>escription of selected adverse reactions</u></p><p><em>Hypoglycaemia</em></p><p>In studies in patients treated with BYETTA and a sulphonylurea (with or without metformin), the incidence of hypoglycaemia was increased compared to placebo (23.5 % and 25.2 % versus 12.6 %</p><p>and 3.3 %) and appeared to be dependent on the doses of both BYETTA and the sulphonylurea.</p><p>&nbsp;</p><p>There were no clinically relevant differences in incidence or severity of hypoglycaemia with exenatide compared to placebo, in combination with a thiazolidinedione, with or without metformin. Hypoglycaemia was reported in 11 % and 7 % of patients treated with exenatide and placebo respectively.</p><p>&nbsp;</p><p>Most episodes of hypoglycaemia were mild to moderate in intensity, and resolved with oral administration of carbohydrate.</p><p>&nbsp;</p><p>In a 30 week study, when BYETTA or placebo was added to existing basal insulin therapy(insulin glargine), the dose of basal insulin was decreased by 20 % in patients with an HbA1c &le; 8.0 %, per protocol design in order to minimize the risk of hypoglycaemia. Both treatment arms were titrated to achieve target fasting plasma glucose levels (see section 5.1). There were no clinically significant differences in the incidence of hypoglycaemic episodes in the BYETTA compared to the placebo group (25% and 29% respectively). There were no episodes of major hypoglycaemia in the BYETTA arm.</p><p>&nbsp;</p><p>In a 24 week study, where either insulin lispro protamine suspension or insulin glargine was added to existing therapy of BYETTA and metformin or metformin plus thiazolidinedione the incidence of patients with at least one minor hypoglycaemic episode was 18% and 9% respectively and one patient</p><p>&nbsp;</p><p>reported major hypoglycaemia. <u>In patients where existing therapy also included a sulphonylurea the</u> <u>incidence of patients with at least one minor hypoglycaemic episode was 48% and 54% respectively</u> <u>and one patient reported major hypoglycaemia.</u></p><p>&nbsp;</p><p><em>Nausea</em></p><p>The most frequently reported adverse reaction was nausea. In patients treated with 5 &micro;g or 10 &micro;g BYETTA, generally 40-50 % reported at least one episode of nausea. Most episodes of nausea were mild to moderate and occurred in a dose-dependent fashion. With continued therapy, the frequency and severity decreased in most patients who initially experienced nausea.</p><p>&nbsp;</p><p>The incidence of withdrawal due to adverse events was 8 % for BYETTA-treated patients, 3 % for placebo-treated and 1 % for insulin-treated patients in the long-term controlled trials (16 weeks or longer). The most common adverse events leading to withdrawal for BYETTA-treated patients were nausea (4 % of patients) and vomiting (1 %). For placebo-treated or insulin-treated patients, &lt;1 % withdrew due to nausea or vomiting.</p><p>&nbsp;</p><p>BYETTA-treated patients in the open-label extension studies at 82 weeks experienced similar types of adverse events observed in the controlled trials.</p><p>&nbsp;</p><p><em>Injection site reactions</em></p><p>Injection site reactions have been reported in approximately 5.1 % of subjects receiving BYETTA in long-term (16 weeks or longer) controlled trials. These reactions have usually been mild and usually did not result in discontinuation of BYETTA.</p><p>&nbsp;</p><p><em>Immunogenicity</em></p><p>Consistent with the potentially immunogenic properties of protein and peptide pharmaceuticals, patients may develop anti-exenatide antibodies following treatment with BYETTA. In most patients who develop antibodies, antibody titres diminish over time and remain low through 82 weeks.</p><p>&nbsp;</p><p>Overall the percentage of antibody positive patients was consistent across clinical trials. Patients who develop antibodies to exenatide tend to have more injection site reactions (for example: redness of skin and itching), but otherwise similar rates and types of adverse events as those with no anti-</p><p>exenatide antibodies. In the three placebo-controlled trials (n=963) 38 % of patients had low titre anti- exenatide antibodies at 30 weeks. For this group, the level of glycaemic control (HbA1c) was generally comparable to that observed in those without antibody titres. An additional 6 % of patients had higher titre antibodies at 30 weeks. About half of this 6 % (3 % of the total patients given BYETTA in the controlled studies), had no apparent glycaemic response to BYETTA. In two insulin-comparator controlled trials (n=475) comparable efficacy and adverse events were observed in BYETTA-treated patients regardless of antibody titre.</p><p>&nbsp;</p><p>Examination of antibody-positive specimens from one long-term uncontrolled study revealed no significant cross-reactivity with similar endogenous peptides (glucagon or GLP-1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Signs and symptoms of overdose may include severe nausea, severe vomiting and rapidly declining blood glucose concentrations. In the event of overdose, appropriate supportive treatment (possibly given parenterally) should be initiated according to the patient&rsquo;s clinical signs and symptoms.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Drugs used in diabetes, other blood glucose lowering drugs, excl. insulins, ATC code: A10BX04.</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>Exenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that exhibits several antihyperglycaemic actions of glucagon-like peptide-1 (GLP-1). The amino acid sequence of exenatide partially overlaps that of human GLP-1. &nbsp;Exenatide has been shown to bind to and activate the known human GLP-1 receptor <em>in vitro</em>, its mechanism of action mediated by cyclic AMP and/or other intracellular signaling pathways.</p><p>&nbsp;</p><p>Exenatide increases, on a glucose-dependent basis, the secretion of insulin from pancreatic beta cells. As blood glucose concentrations decrease, insulin secretion subsides. When exenatide was used in combination with metformin alone, no increase in the incidence of hypoglycaemia was observed over that of placebo in combination with metformin which may be due to this glucose-dependent insulinotropic mechanism. (see section 4.4).</p><p>&nbsp;</p><p>Exenatide suppresses glucagon secretion which is known to be inappropriately elevated in type 2 diabetes. Lower glucagon concentrations lead to decreased hepatic glucose output. However, exenatide does not impair the normal glucagon response and other hormone responses to hypoglycaemia.</p><p>&nbsp;</p><p>Exenatide slows gastric emptying thereby reducing the rate at which meal-derived glucose appears in the circulation.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>BYETTA improves glycaemic control through the immediate and sustained effects of lowering both postprandial and fasting glucose concentrations in patients with type 2 diabetes.</p><p>&nbsp;</p><p><u>C</u><u>li</u><u>n</u><u>ic</u><u>a</u><u>l efficacy</u></p><p>&nbsp;</p><p><u>Studies of BYETTA with metformin, a sulphonylurea or both as background therapy</u></p><p>&nbsp;</p><p>The clinical studies comprised 3945 subjects (2997 treated with exenatide), 56 % men and 44 % women, 319 subjects (230 treated with exenatide) were &ge;70 years of age and 34 subjects (27 treated with exenatide) were &ge;75 years of age.</p><p>&nbsp;</p><p>BYETTA reduced HbA1c and body weight in patients treated for 30 weeks in three placebo-controlled studies, whether the BYETTA was added to metformin, a sulphonylurea or a combination of both. These reductions in HbA1c were generally observed at 12 weeks after initiation of treatment. &nbsp;See Table 2. The reduction in HbA1c was sustained and the weight loss continued for at least 82 weeks in the subset of 10 &micro;g BID patients completing both the placebo-controlled studies and the uncontrolled study extensions (n=137).</p><p>&nbsp;</p><p><u>T</u><u>able 2: Combined results of the 30 week placebo controlled studies (intent to treat patients)</u></p><p>&nbsp;</p><table border="0" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo</p></td><td style="vertical-align:top"><p>BYETTA 5 &micro;g BID</p></td><td style="vertical-align:top"><p>BYETTA 10 &micro;g BID</p></td></tr><tr><td style="vertical-align:top"><p>N</p></td><td style="vertical-align:top"><p>483</p></td><td style="vertical-align:top"><p>480</p></td><td style="vertical-align:top"><p>483</p></td></tr><tr><td style="vertical-align:top"><p>Baseline HbA1c(%)</p></td><td style="vertical-align:top"><p>8.48</p></td><td style="vertical-align:top"><p>8.42</p></td><td style="vertical-align:top"><p>8.45</p></td></tr><tr><td style="vertical-align:top"><p>HbA1c(%) change from base line</p></td><td style="vertical-align:top"><p>0.08</p></td><td style="vertical-align:top"><p>-0.59</p></td><td style="vertical-align:top"><p>-0.89</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of patients</p><p>(%) achieving HbA1c</p><p>&le;7%</p></td><td style="vertical-align:top"><p>7.9</p></td><td style="vertical-align:top"><p>25.3</p></td><td style="vertical-align:top"><p>33.6</p></td></tr><tr><td style="vertical-align:top"><p>Proportion of patients</p><p>(%) achieving HbA1c</p><p>&le;7% (patients</p><p>completing studies)</p></td><td style="vertical-align:top"><p>10.0</p></td><td style="vertical-align:top"><p>29.6</p></td><td style="vertical-align:top"><p>38.5</p></td></tr><tr><td style="vertical-align:top"><p>Baseline weight(kg)</p></td><td style="vertical-align:top"><p>99.26</p></td><td style="vertical-align:top"><p>97.10</p></td><td style="vertical-align:top"><p>98.11</p></td></tr><tr><td style="vertical-align:top"><p>Change of weight from</p><p>baseline(kg)</p></td><td style="vertical-align:top"><p>-0.65</p></td><td style="vertical-align:top"><p>-1.41</p></td><td style="vertical-align:top"><p>-1.91</p></td></tr></tbody></table><p>&nbsp;</p><p>In insulin-comparator studies BYETTA (5 &micro;g BID for 4 weeks, followed by 10 &micro;g BID) in combination with metformin and sulphonylurea significantly (statistically and clinically) improved glycaemic control, as measured by decrease in HbA1c. This treatment effect was comparable to that of insulin glargine in a 26-week study (mean insulin dose 24.9 IU/day ,range 4-95 IU/day, at the end of study) and biphasic insulin aspart in a 52-week study (mean insulin dose 24.4 IU/day, range 3-</p><p>78 IU/day, at the end of study). BYETTA lowered HbA1c from 8.21 (n=228) and 8.6 % (n=222) by</p><p>1.13 and 1.01 % while insulin glargine lowered from 8.24 (n=227) by 1.10 % and biphasic insulin</p><p>aspart from 8.67 (n=224) by 0.86 %. &nbsp;Weight loss of 2.3 kg (2.6 %) was achieved with BYETTA in the 26 week study and a loss of 2.5 kg (2.7 %) in a 52-week study whereas treatment with insulin was</p><p>associated with weight gain. Treatment differences (BYETTA minus comparator) were -4.1 kg in the</p><p>26-week study and &ndash;5.4 kg in the 52-week study. Seven-point self monitored blood glucose profiles</p><p>(before and after meals and at 3 am) demonstrated significantly reduced glucose values compared to insulin in the postprandial periods after BYETTA injection. Premeal blood glucose concentrations were generally lower in patients taking insulin compared to BYETTA. Mean daily blood glucose values were similar between BYETTA and insulin. In these studies the incidence of hypoglycaemia was similar for BYETTA and insulin treatment.</p><p>&nbsp;</p><p><u>Studies of BYETTA with metformin, a thiazolidinedione or both as background therapy</u></p><p>&nbsp;</p><p>Two placebo-controlled studies were conducted: one of 16 and one of 26 weeks duration, with 121 and 111 BYETTA and 112 and 54 placebo treated patients respectively, added to existing thiazolidinedione treatment, with or without metformin. Of the BYETTA patients, 12% were treated with a thiazolidinedione and BYETTA and 82% were treated with a thiazolidinedione, metformin and BYETTA. BYETTA (5 &micro;g BID for 4 weeks, followed by 10 &micro;g BID) resulted in statistically significant reductions from baseline HbA1c compared to placebo (-0.7% versus +0.1%) as well as significant reductions in body weight (-1.5 versus 0 kg) in the 16 week study. The 26 week study showed similar results with statistically significant reductions from baseline HbA1c compared to placebo (-0.8% versus -0.1%). There was no significant difference in body weight between treatment groups in change from baseline to endpoint (-1.4 versus -0.8 kg).</p><p>&nbsp;</p><p>When BYETTA was used in combination with a thiazolidinedione, the incidence of hypoglycaemia was similar to that of placebo in combination with a thiazolidinedione. The experience in patients &gt; 65 years and in patients with impaired renal function is limited. The incidence and type of other adverse events observed were similar to those seen in the 30-week controlled clinical trials with a sulphonylurea, metformin or both.</p><p>&nbsp;</p><p><u>Studies of BYETTA in combination with basal insulin</u></p><p>&nbsp;</p><p>In a 30 week study, either BYETTA (5 &micro;g BID for 4 weeks, followed by 10 &micro;g BID) or a placebo was added to insulin glargine (with or without metformin, pioglitazone or both). During the study both treatment arms titrated insulin glargine using an algorithm reflecting current clinical practice to a</p><p>target fasting plasma glucose of approximately 5.6 mmol/l. The mean age of subjects was 59 years and the mean duration of diabetes was 12.3 years.</p><p>&nbsp;</p><p>At the end of the study, BYETTA (n=137) demonstrated a statistically significant reduction in the HbA1c and weight compared to placebo (n=122). BYETTA lowered HbA1c by 1.7 % from a baseline of 8.3 % while placebo lowered HbA1c by 1.0 % from a baseline of 8.5 %. The proportion of patients achieving HbA1c &lt;7% and HbA1c &le;6.5% was 56 % and 42 % with BYETTA and 29 % and 13 % with placebo. Weight loss of 1.8 kg from a baseline of 95 kg was observed with BYETTA whereas a weight gain of 1.0 kg from a baseline of 94kg was observed with placebo.</p><p>&nbsp;</p><p>In the BYETTA arm the insulin dose increased by 13 units/day compared to 20 units/ day on the placebo arm. BYETTA reduced fasting serum glucose by 1.3 mmol/l and placebo by 0.9 mmol/l. BYETTA arm compared to placebo had significantly lowered postprandial blood glucose excursions at the morning meal (- 2.0 versus - 0.2 mmol/l) and evening meal (- 1.6 versus + 0.1 mmol/l), there was no difference between treatments at midday.</p><p>&nbsp;</p><p>In a 24 week study, where either insulin lispro protamine suspension or insulin glargine was added to existing therapy of BYETTA and metformin, metformin and sulphonylurea or metformin and pioglitazone, HbA1c was lowered by 1.2 % (n=170) and by 1.4 % (n=167) respectively from a baseline of 8.2 %. Weight increase of 0.2 kg was observed for patients on insulin lispro protamine suspension and 0.6 kg for insulin glargine treated patients from a baseline of 102 kg and 103 kg respectively.</p><p>&nbsp;</p><p><u>Fasting lipids</u></p><p>BYETTA has shown no adverse effects on lipid parameters. A trend for a decrease in triglycerides has been observed with weight loss.</p><p>&nbsp;</p><p><u>B</u><u>eta-cell function</u></p><p>Clinical studies with BYETTA have indicated improved beta-cell function, using measures such as the homeostasis model assessment for beta-cell function (HOMA-B) and the proinsulin to insulin ratio.</p><p>A pharmacodynamic study demonstrated in patients with type 2 diabetes (n=13) a restoration of first phase insulin secretion and improved second phase insulin secretion in response to an intravenous</p><p>bolus of glucose.</p><p>&nbsp;</p><p><u>Body weight</u></p><p>A reduction in body weight was seen in patients treated with BYETTA irrespective of the occurrence of nausea although the reduction was larger in the group with nausea (mean reduction 2.4 kg versus</p><p>1.7 kg) in the long term controlled studies of up to 52 weeks.</p><p>&nbsp;</p><p>Administration of exenatide has been shown to reduce food intake, due to decreased appetite and increased satiety.</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with</p><p>BYETTA in one or more subsets of the paediatric population in type 2 diabetes mellitus (see section</p><p>4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>A</u><u>bsorption</u></p><p>Following subcutaneous administration to patients with type 2 diabetes, exenatide reaches median peak plasma concentrations in 2 h. Mean peak exenatide concentration (Cmax) was 211 pg/ml and overall mean area under the curve (AUC0-inf) was 1036 pg &bull;h/ml following subcutaneous administration of a 10 &mu;g dose of exenatide. Exenatide exposure increased proportionally over the</p><p>&nbsp;</p><p>therapeutic dose range of 5 &mu;g to 10 &mu;g. Similar exposure is achieved with subcutaneous administration of exenatide in the abdomen, thigh, or arm.</p><p>&nbsp;</p><p><u>D</u><u>i</u><u>stribution</u></p><p>The mean apparent volume of distribution of exenatide following subcutaneous administration of a single dose of exenatide is 28 l.</p><p>&nbsp;</p><p><u>Biotransformation&nbsp; and elimination</u></p><p>Nonclinical studies have shown that exenatide is predominantly eliminated by glomerular filtration with subsequent proteolytic degradation. In clinical studies the mean apparent clearance of exenatide</p><p>is 9 l/h and the mean terminal half-life is 2.4 h. These pharmacokinetic characteristics of exenatide are independent of the dose.</p><p>&nbsp;</p><p><u>Special populations</u></p><p><em>Patients with renal impairment</em></p><p>In patients with mild (creatinine clearance 50 to 80 ml/min) or moderate renal impairment (creatinine clearance 30 to 50 ml/min), exenatide clearance was mildly reduced compared to clearance in individuals with normal renal function (13 % reduction in mild and 36 % reduction in moderate renal impairment). Clearance was significantly reduced by 84 % in patients with end-stage renal disease receiving dialysis (see section 4.2).</p><p>&nbsp;</p><p><em>Patients with hepatic insufficiency</em></p><p>No pharmacokinetic study has been performed in patients with hepatic insufficiency. Exenatide is cleared primarily by the kidney, therefore hepatic dysfunction is not expected to affect blood</p><p>concentrations of exenatide.</p><p>&nbsp;</p><p><em>Gender and race</em></p><p>Gender and race have no clinically relevant influence on exenatide pharmacokinetics.</p><p>&nbsp;</p><p><em>Elderly</em></p><p>Long-term controlled data in elderly are limited, but suggest no marked changes in exenatide exposure with increased age up to about 75 years old. In a pharmacokinetic study in patients with type 2 diabetes, administration of exenatide (10 &micro;g) resulted in a mean increase of exenatide AUC by 36 % in</p><p>15 elderly subjects aged 75 to 85 years compared to 15 subjects aged 45 to 65 years likely related to reduced renal function in the older age group (see section 4.2).</p><p>&nbsp;</p><p><em>Paediatric population</em></p><p>In a single-dose pharmacokinetic study in 13 patients with type 2 diabetes and between the ages of 12 and 16 years, administration of exenatide (5 &mu;g) resulted in slightly lower mean AUC (16% lower) and Cmax (25% lower) compared to those observed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazards for humans based on conventional studies of safety pharmacology, repeat-dose toxicity, or genotoxicity.</p><p>&nbsp;</p><p>In female rats given exenatide for 2 years, an increased incidence of benign thyroid C&minus;cell adenomas was observed at the highest dose, 250 &micro;g/kg/day, a dose that produced an exenatide plasma exposure</p><p>130-fold the human clinical exposure. This incidence was not statistically significant when adjusted for survival. There was no tumorigenic response in male rats or either sex of mice.</p><p>&nbsp;</p><p>Animal studies did not indicate direct harmful effects with respect to fertility or pregnancy. High doses of exenatide during mid-gestation caused skeletal effects and reduced foetal growth in mice and reduced foetal growth in rabbits. &nbsp;Neonatal growth was reduced in mice exposed to high doses during late gestation and lactation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>metacresol</p><p>mannitol</p><p>glacial</p><p>acetic acid</p><p>sodium acetate trihydrate</p><p>water for injections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the absence of compatibility studies this medicinal product must not be mixed with other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years.
Shelf life for pen in use: 30 days.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2 &ordm;C - 8 &ordm;C). Do not freeze.</p><p>&nbsp;</p><p><em>In use</em></p><p>Store below 25 &ordm;C.</p><p>The pen should not be stored with the needle attached. Replace cap on pen in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Type I glass cartridge with a (bromobutyl) rubber plunger, rubber disc, and aluminium seal. Each cartridge is assembled into a disposable pen-injector (pen).</p><p>&nbsp;</p><p>Each pre-filled pen contains 60 doses of sterile preserved solution (approximately 1.2 ml) Pack size of 1 and 3 pens. Not all pack sizes may be marketed.</p><p>Injection needles are not included.</p><p>&nbsp;</p><p>Becton, Dickinson and Company needles are suitable to use with the BYETTA pen.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The patient should be instructed to discard the needle after each injection.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p><em>Instructions for use</em></p><p>BYETTA is for use by one person only.</p><p>The instructions for using the pen, included with the leaflet, must be followed carefully. The pen is stored without needle.</p><p>&nbsp;</p><p>BYETTA should not be used if particles appear or if the solution is cloudy and/or coloured.</p><p>&nbsp;</p><p>BYETTA that has been frozen must not be used.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bristol-Myers Squibb/AstraZeneca EEIG Bristol-Myers Squibb House
Uxbridge Business Park
Sanderson Road
Uxbridge Middlesex UB8 1DH
United Kingdom

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                20 November 2011
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>